Pritelivir healed all HSV lesions by day 28 in 63% of immunocompromised adults vs 34% with comparators.
News|Articles|July 4, 2025
Key FDA approvals in women’s health: First half of 2025
Author(s)Morgan Ebert
Fact checked by: Celeste Krewson, Assistant Editor
A roundup of the most impactful FDA approvals in women’s health from January through June 2025, spanning diagnostics, therapeutics, and at-home care.
Advertisement
Advertisement
The first half of 2025 has brought several pivotal FDA approvals that are expanding access to care, advancing diagnostic accuracy, and addressing long-standing gaps in women’s health.
Related to this article
A recap of the top headlines from Contemporary OB/GYN in September 2026, spanning ACOG's respiratory vaccine guidance to the launch of the Missed & Dismissed podcast.
A recap of Contemporary OB/GYN's top FDA and regulatory news from September 2026.
The FDA accepted an sNDA and granted priority review for elinzanetant to treat VMS in women receiving endocrine therapy to treat or prevent HR+ breast cancer.
Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.
Experts discuss how obstetric and pediatric clinicians can coordinate to protect newborns.
Experts review ACOG's 2026-27 guidance and the RSV window extension for pregnant and postpartum patients.
Soma Mandal, MD, is launching “Mind, Body, & the Pause: the Perimenopause and Beyond Series” on Contemporary OB/GYN, featuring specialists from across Hackensack Meridian Health.
Advertisement
Advertisement